MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Press releases

Stay current with the latest press releases from within the industry.

$1.5 Billion Annual Cost of Surgical Site Infections Can Be Reduced, Study Says HEALTHPOINT's Preoperative Asepsis System Fights Hospital-Acquired Infection, Expense

Release issued 18th May 2004

(Fort Worth, TX, USA) —A research paper published in the American Journal of Infection Control says a systematic approach to preparing patients for surgery can reduce both secondary, hospital-acquired patient infections and related healthcare expenses across the United States.

Lawton A. Seal, Ph.D., S.M. (AAM), Senior Program Manager, Surgical Division at HEALTHPOINT, Ltd., a Texas- based specialty pharmaceutical company, has published clinical findings on preoperative preparation practices and costs, "A Systems Approach to Preoperative Surgical Patient Skin Preparation," in the April 2004 issue of the American Journal of Infection Control. Deborah Paul-Cheadle, RN, CIC is second author.

The paper deals with preventative measures that address the mounting Surgical Site Infections, or SSI, that account for approximately 500,000 hospital-acquired infections in the United States each year, according to the federal Centers for Disease Control and Prevention (CDC). While skin asepsis technology cannot eliminate deaths from such infections, the study reported in the paper shows that a systems approach can help prevent these hospital-based infections.

"Too many news stories about hospital infection rates focus on time constraints as compromising infection prevention," says Dr. Seal. "The TRISEPTIN® and ACTIPREP® Systems approach supports ease-of-use while effectively countering multi-drug resistant Gram negative and Gram positive bacteria as well as viruses and during the critical wound healing phase".

"We now have clinical data that demonstrates the positive impact The System can have in helping hospitals reduce their Surgical Site Infection rates," states Dr. Seal.

The release of this new study comes at a time when hospitals are looking for ways to reduce the number of hospital-acquired infections, exhibited by heavy involvement in Surgical Infection Prevention initiatives headed by the Centers for Medicare & Medicaid Services (CMS) and the CDC, two groups that are working together to develop a national health care quality improvement project to prevent postoperative infections.

SSIs carry a heavy financial burden, costing U.S. hospitals in excess of $1.5 billion in additional medical treatment each year. Patient stays increase 20-fold and costs quintuple when SSIs are involved in the surgical recovery process. The CDC estimates an average of 12 days and more than $27,000 in additional costs as the result of one of the most common SSIs, Staphylococcus aureus, or "staph" infection. Those costs extend to the patient's recovery period outside the hospital, with 18 percent of SSI cases leading to disability for a period of more than six months.

HEALTHPOINT's preoperative patient skin preparation system products included in the study is comprised of TRISEPTIN Hand and Body Antiseptic and ACTIPREP One- Step Preoperative Prep which are based on a patented technology called Trizenol™. The technology is proving effective for healthcare professionals preparing both their patients and themselves for hundreds of thousands of surgical procedures every week.

An alcohol-based system, TRISEPTIN Hand and Body is much quicker to use than older technologies and is proving more effective as well. The system is sold nationwide by HEALTHPOINT, patent holder for TRISEPTIN. The System offers a powerful alternative to iodine and chlorhexidine gluconate (CHG), formerly the "active ingredient of choice." Trizenol has three key elements: a fast-acting, broad-spectrum antimicrobial active ingredient —ethyl alcohol; emollients with surfactants to condition the skin and remove dirt and organic debris; and, a preservative system to prolong the antimicrobial action of alcohol.

The system includes:

1. TRISEPTIN Hand and Body Antiseptic is used by the patient to shower prior to surgery to help reduce the microorganisms that can cause surgical site infections. The iodine-free, CHG-free formula reduces the risk of irritation and allergic reactions and kills viruses as well as bacteria. It is available in retail pharmacies.

2. ACTIPREP, a one-step preparation solution used by staff in the operating room, cleans and prepares the entry area on the patient. ACTIPREP reduces the time from the four minutes necessary for traditional preps to about two minutes.

The American Journal of Infection Control is published by the Association for Professionals in Infection Control and Epidemiology.

Since its inception in 1992, HEALTHPOINT has established a U.S. presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for tissue management, dermatology, and surgical. An aggressive research and development effort has brought HEALTHPOINT's unique technologies to the market, setting the pace for its highly trained field sales organization of direct sales representatives. HEALTHPOINT, with over 290 employees, is a DFB Pharmaceuticals, Inc. affiliate company. HEALTHPOINT is based in Fort Worth, Texas. Visit HEALTHPOINT's web site at www.healthpoint.com. Also headquartered in Fort Worth, DFB provides technology- driven products, outsourcing services, and licensing opportunities to the healthcare industry worldwide through its affiliate companies, contract partners, and branded marketing organizations.

Company details

If you want to find out more about the company visit DFB Pharmaceuticals, Inc. profile.

Latest DFB Pharmaceuticals, Inc. press releases

More Press Releases

Related categories

Therapeutic target
Hospital and Surgery
Infection control

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us